- Home
- KUKE vs ALLK Comparison
KUKE vs ALLK Comparison
Compare KUKE & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- ALLK
- Stock Information
- Founded
- KUKE 2002
- ALLK 2012
- Country
- KUKE China
- ALLK United States
- Employees
- KUKE N/A
- ALLK N/A
- Industry
- KUKE Other Consumer Services
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- KUKE Real Estate
- ALLK Health Care
- Exchange
- KUKE Nasdaq
- ALLK Nasdaq
- Market Cap
- KUKE 49.8M
- ALLK 58.0M
- IPO Year
- KUKE 2021
- ALLK 2018
- Fundamental
- Price
- KUKE $0.95
- ALLK $0.65
- Analyst Decision
- KUKE
- ALLK Hold
- Analyst Count
- KUKE 0
- ALLK 5
- Target Price
- KUKE N/A
- ALLK $1.67
- AVG Volume (30 Days)
- KUKE 306.7K
- ALLK 302.5K
- Earning Date
- KUKE 10-29-2024
- ALLK 11-11-2024
- Dividend Yield
- KUKE N/A
- ALLK N/A
- EPS Growth
- KUKE N/A
- ALLK N/A
- EPS
- KUKE N/A
- ALLK N/A
- Revenue
- KUKE $15,080,878.00
- ALLK N/A
- Revenue This Year
- KUKE N/A
- ALLK N/A
- Revenue Next Year
- KUKE N/A
- ALLK N/A
- P/E Ratio
- KUKE N/A
- ALLK N/A
- Revenue Growth
- KUKE N/A
- ALLK N/A
- 52 Week Low
- KUKE $0.48
- ALLK $0.54
- 52 Week High
- KUKE $4.07
- ALLK $3.41
- Technical
- Relative Strength Index (RSI)
- KUKE 55.89
- ALLK 50.32
- Support Level
- KUKE $0.81
- ALLK $0.63
- Resistance Level
- KUKE $0.92
- ALLK $0.70
- Average True Range (ATR)
- KUKE 0.09
- ALLK 0.05
- MACD
- KUKE 0.04
- ALLK 0.00
- Stochastic Oscillator
- KUKE 98.40
- ALLK 33.33
About KUKE Kuke Music Holding Limited each representing one
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.